Treatment of Behçet's disease yesterday and today

Uveitis due to Behçet's disease belongs to those types of intraocular inflammation with a poor visual prognosis. Despite early treatment with corticosteroids and immunosuppressants, patients often become blind. With the so-called biologicals, highly effective drugs are now available which very...

Full description

Saved in:
Bibliographic Details
Published in:Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2012-06, Vol.109 (6), p.568
Main Authors: Deuter, C M E, Zierhut, M, Doycheva, D, Kötter, I
Format: Article
Language:eng ; ger
Subjects:
Behcet Syndrome - diagnosis
Behcet Syndrome - drug therapy
Biological Products - therapeutic use
Blindness - prevention & control
Humans
Immunosuppressive Agents - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Uveitis due to Behçet's disease belongs to those types of intraocular inflammation with a poor visual prognosis. Despite early treatment with corticosteroids and immunosuppressants, patients often become blind. With the so-called biologicals, highly effective drugs are now available which very rapidly lead to quiescence of intraocular inflammation and which successfully avoid further uveitis relapse. Recently, an interdisciplinary group of experts on behalf of the EULAR developed nine recommendations for the treatment of Behçet's disease. Two of these address ocular involvement. Compared with TNF alpha antagonists, interferon alpha offers the advantage that even after cessation of treatment a high percentage of patients remain in remission. This article provides an overview on current medical treatment of ocular Behçet's disease.
ISSN:1433-0423
DOI:10.1007/s00347-011-2504-9